Marshall Fordyce sold $702k of VERA
PRESIDENT AND CEO at Vera Therapeutics, Inc.. 18,500 shares at an average of $37.93, traded Jun 23, 2026, filed Aug 12, 2026.
Score components
- +25RoleCEO
- +21Trade size$702k at market
- 0Share of holdings soldSold 7.3% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001859453-26-000012, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 23, 2026 | MOption exercise Class A Common Stock10b5-1 | +18,500 | $2.90 | $54k | 253,744 | Aug 12, 2026 |
| Jun 23, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -18,412 | $37.93 | $698k | 235,332 | Aug 12, 2026 |
| Jun 23, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -88 | $38.43 | $3,382 | 235,244 | Aug 12, 2026 |
| Jun 23, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -18,500 | $0.00 | $0 | 572,051 | Aug 12, 2026 |
Related signals
Other insiders at Vera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $685k 18,500 shares | -7% | |
| 10Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $650k 18,500 shares | -7% | |
| 11Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $680k 18,500 shares | -7% | |
| 20Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $2.0M 46,250 shares | -16% | |
| 35Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $2.0M 46,250 shares | -23% | |
| 26Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $702k 18,500 shares | -9% | |
| 26Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $680k 18,500 shares | -8% | |
| 30Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $1.0M 22,951 shares | -9% | |
| 39Weak | Vera Therapeutics, Inc. | Robert Brenner Chief Medical Officer | $90k 2,151 shares | -4% | |
| 61Notable | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $711k 16,925 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.